IMGN - Earnings call transcript Q3 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to ImmunoGen's Third Quarter 2020 Financial and Operating Results Conference Call. Today's conference is being recorded.

Now I'd like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications and Investor Relations. Please go ahead.

Courtney O'Konek

Good morning and thank you for joining today's call. a progress that financial and issued of a results. we recent our third today, press includes release summary Earlier quarter XXXX can This of Investors a and Media be call & immunogen.com. press the found of web section under release this stream Enyedy, Mark us Anna Altschuller, Business and President and our Officer our for Chief Chief Medical will are our today CEO; Financial join Chief Q&A. me our With Coen, also Officer; Berkenblit, Susan Officer; Stacy

over key During three the today's business will for and last review our milestones. accomplishments call, results financial months, the we upcoming

And our the results statements. call the will During and investment our we use Mark. with discussion, to the over filings. are of differ forward-looking uncertainties such that, statements, from I'll ImmunoGen and with an in in actual turn materially associated risks may included Descriptions SEC

Mark Enyedy

$XX pleased Thanks, months, and the partnership Courtney. we in joining to in milestone the extensive managing hospitals & commercial and with development Lazard in China. is to bringing the access deal look our its Ropes Greater and second tiered capabilities, large additional and Starting This fruition. of our cancer women market with operating Huadong sheet strategic ovarian in were that and Huadong's local We've Medicine commercialize generated this to Greater you business further with million a of to COVID market us momentum China. And across living program, Gray realize mirvetuximab to lead bring bring environment. challenges sales. us of $XXX the company, Its payment payments pharmaceutical achieving support for an last working along with outcomes milestones largest mirvetuximab world. upfront balance We collaboration And the to develop thank I in number today. network allow days and improve strengthens region. announce of teams with in regulatory research, for on to a to over Good in good the million to the up important the the Huadong our to everyone forward significant royalties potential several the mirvetuximab's their thank will more morning, while of to with

and we we first our on Beyond QX and Greater potential XXXX track China, line urgency with for patient's U.S. are sense are to prepare the continue SORAYA a both working mirvetuximab site advance the of execute year. And trials to from next activation of SORAYA this launch MIRASOL. enrollment in end, report to To top and pivotal on in in for data

a we with addition combining committed monotherapy earlier other lines to therapy In were label, of agents. to by into moving potential

we the earlier regimens and forward year, With a and in the shared encouraging are our at ASCO best approach data benefit ESMO label we look to with to future working expansion this to path define call. the of our combination sharing

XXX need stage task from of define to for for therapy refractory to BPDCN rare and further other the safe to We're IMGNXXX continuing aggressive programs, we of breakthrough and evaluate with the the relapsed delighted effective malignancies. earlier FDA to were this our FDA designation underscoring receive development Moving BPDCN for and hematological engaged treatments AML treatment or and while cancer. for

detail. programs review we half the payments XXXX. facility, Anna over our expect future with second development our existing cash and balance in to operations execution business our effective Anna? and the our of partners sheet have our more further in through that, now I'll of turn strengthened With into deployment to call Finally, our ATM clinical from to fund together

Anna Berkenblit

Thanks Mark.

MIRASOL, IMGNXXX, with stage as in pipeline earlier of we our IMGCXXX pleased enroll We patients the and our SORAYA, are trials. progress mirvetuximab and

monotherapy. mirvetuximab on are track with We

top the XXXX expect XXXX. the to third we support approval BLA end during the in line SORAYA, of XXXX quarter submission For of before and data

report data expect study For top the in line to for MIRASOL, XXXX. first this we half of

platinum Moving you doublet lines from at I to recurrent response forward rate median where months. to response of of or the FR alpha regimens. listing, XX% of regardless in could generated a and cohort presented months bev carboplatin ESMO to the survival mirv mirvetuximab and observed bevacizumab also ovarian we mirvetuximab ASCO XX.X profile. sensitive We remind received status. of platinum rate cancer of and with of May, XX overall and observed evaluating expression, an at patients median The bevacizumab to high with data presented levels will of receptor two data and sensitive XX% observed our with of have XX.X our duration responses progression medium up cohort alpha, combination free confirmed We favorable with folate overall triplet in high final date given in support The response mirvetuximab platinum tolerability with compendia patients data in combination who September. therapy. prior a evaluated of triplet

quickly seek earlier formal therapy. of lines to expand in registration to to path mirvetuximab define into We are working for a combination and

our to earlier solid and programs Moving targeting tumors. portfolio, hematological stage both our advanced we malignancies

this refractory abstract poster an our from BPDCN. combinations residual are well IMGNXXX to frontline venetoclax patients study induction agent in cohort combination minimal trials relapsed with released as and In multiple monotherapy relapsed azacytidine presenting forward AML. continue BPDCN largest progress oral at in December. the positive with We ADC, week, the included, the progress cohorts AML following And in a expansion data XX-patients single in with ASH prospective ASH IMGNXXX disease cohorts in updated and refractory We BPDCN to including anti-CDXXX and monotherapy and comprising expansions AML earlier presentation. look on as therapy the with BPDCN monotherapy

rate durations an favorable We XX% [ph] the heavily unmet presentation months. a with on profile response capillary Elzonris. with demonstrates of response prior X.X are forward pleased tolerability clinically prior hospitalization these syndrome Xth. without including in months overall those Premraj's meaningful Dr. for chemotherapy, with prior X patients and high need, look safety pre-treated activity also We need and IMGNXXX intensive Saturday, leak transplant or December With administration. to over for and from ranging to of

Finally, I escalation pleased enrolled first have are Phase study IMGNCXXX. to a dose evaluating we in our patient

Our breast atom financials. being the to back which is forward to further trial. ADC review nine pancreatic, targeting non-small I'll this in over that, co-developed and advancing macrogenex and including turn colorectal, call negative Susan Susan? With with to look lung, cell tumors triple the solid gastric cancer

Susan Altschuller

Thanks, Anna.

were primarily trial with related the $XX.X in third revenues. million revenue, fees. $XX.X was advancing by from XXXX, XXX For by driven of we quarter third the XXXX. of million million in million and partially nearly of to cash. This from increased the Operating which of $XX.X in quarter third our G&A At to compared end for greater expenses expenses XXXX, to costs generated quarter, came we all compared increased offset restructuring expenses lower noncash SORAYA million professional clinical the quarter studies, had the were $XXX.X increase R&D $X.X MIRASOL, million due expenses. $XX.X third royalty of

and for a payments Greater executed newly revenues a rights and end, aftermarket Huadong agreement with achieved million million. and from between million from expenses financing. include year-end Importantly, financial we our milestone partnership Received the in between And be the Medicine. to in license we September. an between payment and with upfront Viridian $X $XX expect to to guidance, note agreement not guidance to be from proceeds $XX for $XXX $XXX impact our quarter Novartis XXXX million. in Operating in $XX million million will $XXX development our our Obtaining Huadong now cash Received to million $XX million the our mirvetuximab payment Please net Medicine from potential receive a at that revenue $XXX be China. any related does in brought from subsequent million. to upfront

We accelerated the are approval launch. support commercial for to in potential manufacturing mirvetuximab cancer, platinum-resistant planning in investment XXXX of ovarian and are increased for related in for preparing

operations cash of Mark. the the I With partners investments, the cash that into With of half anticipated second expect these will and from to XXXX. over back addition will we receipts call fund current turn that,

Mark Enyedy

Thanks, Susan.

over significant a finish We're XXXX strong of closing business future. Just the a course about few the with year. excited remarks. look to progress forward We've the to and made the

mirvetuximab, of for our program. benefit label and for a on cash execute submission data lead strong position for of BLA initial milestones to for an number path experienced business the the BPDCN, the positioned registration and generating XXXX, well IND to a With we've XXX including IMGCXXX finally as from and an expansion IMGNXXX. in Define management as and important a the team data pivotal

the open what for that you call So apprised I Operator? the times company. questions. look are exciting of and With we'll forward keeping progress for to our

Operator

Instructions]. [Operator

from Our question John line first the of from Newman comes Canaccord.

open. Your now line is

John Newman

guys. morning, taking question. for Thanks good Hi, my

on had interesting a BPDCN, as the data Just breakthrough well IMGNXXX. status. the question you've with really assay become This that presented has as for

about curious how because neck refractory you're relapsed neck in with pathway. was your the look in you if stem thinking population. registration where basically you're Just the Especially about CR rate, at line

So you're terms of Thanks. about how just registration? this thinking curious as to developing in asset

Anna Berkenblit

BPDCN. activity be And terms path the time our sharing of registration very Around sharing refractory forward ASH. we in also in updated we're data pleased plans at We're will relapsed we John. Thanks, ASH, look seeing with the of to forward.

path was year forward with FDA we previously, look sharing discussed around forward define our we've to that and of As the to a this to meet ASH. time goal

John Newman

Great. Thank you.

Operator

Thank you.

from comes Schmidt of the Guggenheim. question Michael line from next Our

open. now is line Your

Michael Schmidt

maybe much Hi, PRs might note additional And converted as on you at IMGNXXX, the good did conference? can ASH you here on I little CRC. a some data guys, color to the from progress of that congrats more well. bit the we how morning later expect and On provide

with if wondering, indication? Just general a that's in phenomenon this ADCs

Anna Berkenblit

Thanks, Michael.

recall ASH, BPDCN rate. XX months ASH X time over X.X we evaluable. were the year, we see abstract you at we response duration where patients patients, the at cut of have saw had you you the for of may And as a And months. off of XX% enrolled we now, last do information, three have had for to XX whom So response enrolled data

duration quite nice response of relapsed those in refractory is this data So population.

enroll, set continue on present data the We and will updated data we ASH. at to entire

Michael Schmidt

was Should structurally that a BLA based rights? might My wondering Just on Okay, question, operational they might submission? to to may how opt-in guess. out file BLA speaking? opt-in decide Pharma understanding Jazz that data? I these prior great. the affect need this to work And you then How an

Mark Enyedy

thanks, Michael. Yes,

opt-in So the are is there periods. agreement works two the essentially way

this of filing The related nuance we to And second first the of agreement is the in an day, the from initiation the of development sign the AML. through runs There's which the a BLA from opt-in the probably BPDCN, for beyond until interim that call. scope AML. time for pivotal runs bit period little up filing

the in, I development till So early have is can around up that BPDCN, I as opt-in there's nuance characterize if the it there's way they they not And of opted would initiation simply where some said, period. AML. deferral a pivotal for

Michael Schmidt

Okay, you maybe duration Can thank makes been we then may when with think And study comment in on to of Anna, I seen know of Elzonris? therapy a that your about treatment market duration compare difference. has size, big you. how

Anna Berkenblit

about So talking our response. I transplant. a that start with in absence just remind Michael, you it's is duration response Again Elzonris But of of anti-drug the in in be of the the little duration tends would to if to Elzonris absence response antibodies, Elzonris terms And develop in and in three-month of us median transplant you the early for duration of rather range. of brief. actually comparing do

north pleased Elzonris. So, months. chemotherapy, far, thus nine some enrolled heavily of We've had intensive post and the post we've with durations patients some post-transplant response of that we're pretreated,

Michael Schmidt

congrats all And Thanks. Great. on progress.

Mark Enyedy

Thank you.

Operator

you. Thank

Hsieh next Blair. line of Our comes from question the Andy from William

Your line now is open.

Andy Hsieh

my taking question. for on congrats the all Thanks Great. progress. And

quick me. a Just for one

guess China I is with Street the not So, the pathway. familiar regulatory

be wondering, just to a full-blown FORWARD order I both sufficient. sort marketing needs in sites, MIRASOL Phase or SORAYA authorization? basically study, and the what or done approval bridging Is be to of there X gain I'm So needed I, would guess, complementing a just some regulatory trial

that would Thank be So of color any super sort you. on helpful.

Anna Berkenblit

Sure, Andy.

reasons of because in Huadong So chose in drugs we expertise the developing China. of one their

we forward China. so in really clarifying And to the path look regulatory for mirvetuximab

to to expedient the need get so patients alignment will regulatory we And Chinese China. that path regulators with will out working confident are the do with so. Huadong figure to in in we're data doing and most to generate we We

Andy Hsieh

Got it. Thank you very much.

Operator

you. Thank

the line in Our next Jefferies. goes question from Biren Amin of

is line Your now open.

Biren Amin

supported for BLA guys. on that's you taking data questions. Maybe want by my for will considers a Yes. Hi, the wait mirvetuximab. before think it Thanks Do SORAYA? FDA MIRASOL to

Anna Berkenblit

base case to delivered our allow before There's us ahead next year. have is SORAYA track that year filing certainly of a assumption. on be data possibility to a the not end to are really a

have rationale data. they so for don't wait the think there And them we MIRASOL any unless be to some for will concern,

Mark Enyedy

And situation approval maybe the study on issues, a just obviously they gained and delay speaking there's on sense play they in Phase shortly delay had had the right the ultimately, to again. X arm study [indiscernible] thereafter. they manufacturing [indiscernible] out But

prepared that can And is a where FDA to data unmet front so are in I need you basis them. think have significant the action take on of the that of particularly

Biren Amin

the a in you past that for with company would would And call in you call. move today think study listing. it. you've future strategy combination, I the forward Got plans talked reconsidering about the compendia then this But a know registrational potential some is And strategy? you your I potentially mentioned Are in I setting? that in disclose guess, on you

Mark Enyedy

Yes. think is attitude. The about it to way

So that basis be good the to submitting combination we've to would the U.S. the reimbursement those the data. support compendia and it are correspondingly in of a And lot generated for data listing

know, of of ability the we a data. you absence in to the terms As promote would constrained be those in label

best label really two the is we be either Carboplatin. And ultimately line the earlier Avastin to will with expansion so gain patients. or in there a combinations, likely And think goal approach

working as speak. So through that's we're what we

Biren Amin

we safety a Okay. think, line? XXX. this other any you're any just what's at And in front capillary on program. I I Are then in BPDCN Elzonris? that seeing maybe if not this program with evaluating I that with guess, as seems with it look this an those because or then plans your Because saw And there question the syndrome we've leak driving seen profile, CDXXX

want to profile? just So driving understand of safety kind what's the

Anna Berkenblit

Yeah.

open. the excited actually So, just recently and is development amended, in about frontline We further the relax patients. IMGNXXX setting. We protocol enrolling of in started And refractory that. certainly currently we're frontline it both is the

the think, profile stopped hospitalized. not to really Elzonris. to many leak required the it's not and a that large ago. diphtheria perspective can that part I been clear So that's has due tolerability IMGNXXX from very We're had have fatal syndrome diphtheria and safety a very in favorable toxin has And on conjugate. years seen be safety with we working conjugate toxin profile. capillary be has And ImmunoGen

those cytokine with other release it of terms be can In and targeting CDXXX biospecifics. ways of syndrome that biospecifics there's for problematic certainly

I quite at this we're the that seeing. So pleased with think profile we're point, safety

Biren Amin

Great. Thank you.

Operator

Thank you.

Jessica Our JP next question comes Morgan. on the line from Fye of

Your line is now open.

Jessica Fye

taking with post on my of good annual talked the of you What resistant into know guys, for see minute. ovarian focused patients. your slides just you of for specifically. therapy? Hey But frontline about more the to thanks maybe some X question. ovarian incidence One ovarian drilling morning, that [indiscernible] as I platinum is cancer do number in X

Mark Enyedy

we would of think the market patients. higher positive add more our To label fully Yeah. that that, be annual one the proposed X,XXX alpha level, for into a receptor are criteria at those incidence

Jessica Fye

you do that… And think Okay.

Mark Enyedy

if with away And XXXX. you treated Avastin take it jumps Jess, about we to previously the criterion think

think from So which we reasonably X had prior and sample, half look half a FORWARD when did at the is not. data about the Avastin representative we patients

Jessica Fye

Got it. in that or Europe? is in And US

Mark Enyedy

Yes, are data. use combination US a those numbers. We of

looking Flatiron cohort. physician point. data at at a then get buy Ipsos from we the date supplement through an And that we with DRG. is those a starting DRG starting have we're agreement also numbers. with And to where we and The So longitudinal survey

Jessica Fye

control trial anticipate mirvetuximab? a for there European SORAYA that meeting support Got from it. data like And do Or MIRASOL? could is possibility you the approval

Mark Enyedy

Yes.

results go is single the for done of to at appetite a Their study sure. support past it limited it EMA arm my in for about seen SORAYA the has life we been to historically I've So through things in talk will oncology. genzyme. with

support the So we that MIRASOL if in would doesn't, And the go then EU. approval bear be out doesn't conversation. it fruit, would will that that if full

Jessica Fye

you're mirvetuximab forward in about then Okay. of And kind the sounds path thinking like for it combination.

those most opportunity? are the there maximize possibilities best and kind which of in what your view of would So, the commercial interesting

Mark Enyedy

Yes.

If and the of you ovarian fair on get most we're agent either look actually a But neo-adjuvant there's looking platinum-based de-bulking, following or doublet amount patients cancer Avastin. a surgical patients third And at that been triplets in today, diagnosis initial use. IST. at with

And substituting be to The Paclitaxel, for so firma in we the large, doublet mature very there triplet or market generated some data very shared obviously, data the large market is and nice But I think, that at study. at the that ESMO. we perspective, that's highest a opportunity. going a triplet challenge opportunity would be mirvetuximab from

looking we're was line a are earlier we into therapy. to similar It Either the [ph] what saw alpha patients so patients platinum patients ASCO there, opportunities rate at levels We of compelling. receptor were were high shared of where agnostic. And we who data in of that response move those mix had to strategy resistance quite a expression. data our the or at using patients. with full sensitive Lyme rate a in but later the XX% response terms And the a

marrow, patient those So, going third are lot that that based regimen looking platinum a of are platinum giving a pays platinum, why platinum or population couple remain sensitive to tired, of reasons there what in etcetera. happens after non-platinum Because separately hypersensitivity, at sensitive. sort physicians are is a bone platinum patients lines later, line not to of agnostic after of

patients doesn't is what a growing regimen where population And that include those our platinum. data we of so see combination in a

could mirvetuximab a nice example, them. for for Avastin plus very alternative So, be

are those terms in of thoughts our So, expansion. label

Jessica Fye

Thank Got it. Sure. you.

Operator

you. Thank

Boris of line Peaker question Cowen. next from from the Our comes

Your open. line is now

Boris Peaker

patients my the into folate SORAYA trial, you're new as fall receptor for you finding MIRASOL as it. to of as category taking the I'm your thanks curious just positive What enrolling based on fraction well are Great, assay? for question.

Anna Berkenblit

assay program, about plus patients So, XXXX TF we beginning it's the assay. assay. X new It's would know from have Boris, And from [indiscernible]. not the that over exactly we tracking testing a the that as an are of expect, used XX% we we're

Boris Peaker

taking my question. for Thanks Great.

Mark Enyedy

Sure.

Operator

you. Thank

Our next question Catanzaro comes from from of the Sandler. line Joe Piper

is Your now line open.

Joe Catanzaro

thanks from taking with How nice one much think guys, my question the China on And your quick potentially Europe? I more Maybe could so under Greater guess you do consistent you the for future? here. namely belt Hey, about additional ex-U.S. mirvetuximab. guess, now one. partnerships for as over just deal how potential readout forward? view moving SORAYA in I asset, create near whether that your needs is maybe and And that largely around cash value Thanks. you a MIRASOL

Mark Enyedy

Europe. Yeah, you say need multi-variable a Joe. would what be in would the for versus value is market to on fairly this think need to in than is looking equation more We've I physician - mean, degree infrastructure. analysis to to we're what offset so well, terms the done targets, here, national launch patterns treatment That's for and Europe. commercial it's a some of by And U.S. concentrated bring particular at and it level, we concentrated if partner a product the I which resources Actually the in bringing the bear on.

pivotal Europe So finance to what been a estimates ambit of you like at region ImmunoGen, company to particularly of similar with medical commercial within positive infrastructure, the what data. of in a you and region to sort on comparison. the the our of affairs, back end up you But certainly look able when have

there a lot advantages said, as well. partnering So are to of that

with And that data we hand. in in something pivotal evaluate, so particular that's will positive

Susan Altschuller

upfront strength. half guidance that second and with would China outlay a feel of XXXX. add we've updated from the we I cash is, And million of now thing deal One for we're proceeds in position $XX ATM, the until

that want now partnerships, the have technology that decision to optionality we strategic So because right on we spent this quarter. do we

Joe Catanzaro

Thanks got taking it. my Okay, for That's helpful. question. Thanks.

Mark Enyedy

Sure.

Operator

you. Thank

Leerink. Our comes line next Chang SVB from question the of from Jonathan

is line Your now open.

David Ruch

our guys. Hey, morning, David taking on Jonathan. Thanks for questions. Ruch is This good for

color And response presented, have you when of for adjuvant with the monotherapy data the treated last on you initial do could then XXX, and second, AML, provide any combination the in please? of present in ASH cohorts from you have the guys enrollment combos or year? we patients any question see duration plans progress First might data at XX to from

Anna Berkenblit

that data of for that, So for monotherapy write AML ASH data. IMGNXXX. response when we for year last we presented We anticipate manuscript that duration the a will we at provide

We to midst time call investor provide the conference planning combinations the update would IMGNXXX. escalation. of the progress of study needed trial progress a the for ASH. azacytidine the And class poster a with the to that an Moving the of event be describing in combining midst with in have we're time appropriate in combinations, And ASH, that and us design an triplet. on as a dose around at are for the we do

David Ruch

that And just you. Thank when We've second, just [indiscernible]. provide thyroid this our economics timing anything sales the could impressive then you'd here eye I opportunity Topezla further you promise wondering within I And regulatory about on noticed any was opportunity? disease Got a figures seen some else this And on filing. from highlight IGF collaboration of the I of year it. Thanks lot. the and [ph]. specificity potential guess already if your

Susan Altschuller

Sure.

numbers to do in recognize have We think that approximately of position $XX supposing move structure it's fashion. we're well we And in up type million in to placed sales They're million the in a milestones development milestones $XX So program. Viridian. milestones upfront and upfront that to forward. and royalties opportunity a on deal, but with traditional is, do on that the not

the you at And on have in ImmunoGen. eye pursuing it's a asset indication, to potential. has which complimentary disease very them cancer know, that thyroid promising As we're focused think here this we

David Ruch

lot, on progress. Great, thanks a the congrats and

Operator

Thank you.

the Kennen line from MacKay comes from of RBC. Our next question

is open. line now Your

Kennen MacKay

and run question. there? fielding wondering, we of And relating birdie these Or question. another platform out additional heard tech, much of your here. and looking Mark, be interest incoming you what's or can to similar remarkable were potential combination congrats payload been the strategics the more on Or Hey, deal taking or most nine so the really access was earlier Is cohorts from I for big a recently and days? that And to to the therapies thanks it mirvetuximab mirvetuximab? linker that interests pipeline sort for trials about? year

Mark Enyedy

Yes.

is, interest tends it signed two the attract that Obviously, the of inbound a the In of So is, mirvetuximab. of the is other there's At a what the deal China, of the we've stage get it of that attention. there in ADC with the spectrum, to imagine, oncology say for interest a lot we at a end but And approvals. I that can a What recent mean lot spectrum. late terms would as is assay. platform, I of ends Greater around the it's you in lot underlying space, success technology. by in

we with are catalyze Veridian. but discussion similar the So to, inbound, fielding

And over so. of out our so, I that a see important with integrates the kinds those last, it we're XXX, And came as the innovations or are progress, of of entertaining. we decade labs think things the number really which example, half for

payload also and will engender some In greater linkers, of that progresses, I those interest. that see probably, that, we terms antibody even program of and think engineering people

those And broadly. deploy technology so platform being able we're about and more the to excited things

programs do on it partner those to where others In [indiscernible] what interest the XXX that innovation there. both we're and But intrigued that's the so and is. getting come not are knocking. have is has middle any So, our

Kennen MacKay

minimization, ImmunoMedics a there's in Obviously, been And after elaborating little a the agencies acquisition. of maybe interest lot just strategic competitive that bit. on

really, combination [indiscernible] deals ovarian rather there Partnering a now stand Maybe on partner seen sort field anything are of cancer? checkpoints potential that wondering drug a- checkpoints. that specific immuno-oncology combination interest the in the ADCs thinking in any partners out we've around with ovarian cancer, as are I'm combination of better the evolution maybe not if relating of send some And in sense, and with of

Mark Enyedy

Yes.

and move may initial Merck were ovarian patients. setting in with resistant quite remember the And combining Keytruda with So, platinum responses that you Ken we encouraging. cancer forward

of contribution cohort, efficacy population agent significant in when didn't what typically we've out beyond expanded see However, that we seen mirvetuximab. terms a we with the in single

some that further. But think, words And and these adverse pointing pan There Anna and really I so Alfred the not this. by checkpoint that was they lab, didn't It's encouraging based synergy have Switzerland. Paleo. to particular has data. add data, between we a to in preclinical I been tubulin paper to it. pursued showed I in we're a not was acting have say the And what it's other out. But saying inhibitors is, which an few agents would to what early interesting

Anna Berkenblit

Yeah.

checkpoint would we concept in proof studies checkpoint as failures [indiscernible] for the unfortunately, cancer very most ovarian ovarian achieve III not so at cancer. think recently So treatment go in of and I with revolutionized have the I several other this ovarian to consumers. many really [indiscernible] mutational is have been even tend far not paradigm. to say inhibitor tumors Phase inhibitors could unlike where the in the There cancer in inhibitors [indiscernible] javelin checkpoint point with

there's biology with would to So the be new currently pursue Unless unlikely. identified inhibitors. think in that's combinations strong for the a us checkpoint I target available

Mark Enyedy

we at have the are the ADAMX checkpoint example that look moving opportunity. types inhibitors, shown that tumor portfolio I where the the for IMGCXXX, the we program with with If think part in creates activity earlier of

So we're it. to absolutely open

place As with I didn't said, want us Anna we we anything mirvetuximab for a see that heavily. that made bet is this identify, to experiment ran ovarian say the the and and reasons cancer

Kennen MacKay

you Got sir. it. very Thank much,

Operator

Thank you.

from question HC comes of line Our [indiscernible] Wainwright. next from the

now line Your is open.

Unidentified Analyst

have asked. my is HC of This Wainwright. questions Most RK you. from Thank been

the partnered is release? that ADC also progress on the give XXX. have This a the Could to data And you anything trial? you question have regarding ADAMX-Targeting with just us timing MacroGenics. Just some of as for color

Anna Berkenblit

on dosed announced our delighted have to we're RK the Yes, first call we patient. earnings that

trial solid tumors in study. of expressed and way. highly is its on normal is dose not plus escalation a three standard is And of beauty And so tissues. a the three multitude It's on it that ADAMX the

a is allowing negative gastric, nice there's cancer. cancer, and So differential triple there go cell breast non-small colorectal, that after lung us pancreatic, to

data, sufficient design look well. the So sharing three we plus to we three anticipate it. And should have enroll we that when forward

Unidentified Analyst

Thank you. my taking question. Thanks for

Operator

you. Thank

next Our from Newman comes John of from Canaccord. the line question

open. Your is now line

John Newman

the Hi, guys, up. thanks taking follow for

Just could in should the will So front of how study. study get the maybe you in just how together maybe if longer put that be bigger that there. just a might line mirvetuximab you with can also But the study obviously, on combination cooperative if we ImmunoGen activity at down you're look run, I but wondered that road that groups? term and that's If Avastin? know, curious, line think a about platinum, in bit seeing with be combination a to as that given a to not be just I ovarian. will curious with use elaborate Thanks. would in down the

Mark Enyedy

Yes, Jess. the we revisit with so to just have conversation

at described. We label these patients to regimens the are expand combination platinum recurrent sensitive agnostic could include that or I patients platinum that looking

group think to get of And To indication, step. I involve so a I the that the is think likely given cooperative study, frontline would a next likely effort. scale that

registration impact [indiscernible] was see to to what here started of That's for IST and for or up of study. step So earlier the top move to what you through. agnostic the patients. we address and the sensitive lines expansion also really something today I tell label going these need into right the can't platinum queue recurrent also be in think we next to is some want path into sitting do this the platinum And what exact would is and there. would [indiscernible]

So in line And from near segment that stay look I for in platinum sensitive patients. wherever platinum patient or agnostic of tuned. think later term us terms

John Newman

Great, thank you.

Operator

to the At you. I team remarks. further turn I'm closing questions. showing no would like call over this for Thank time, the back to

Mark Enyedy

to we and seeing with progress much. look as you Great, the today the appreciate the we thanks forward ASH in all make New and business. Year further Well, and interest at very

thanks So very much.

Operator

Ladies call. for today's gentlemen, this participating. and concludes conference Thanks

You may now disconnect.

Immunogen (IMGN) 6 Nov 202020 Q3 Earnings call transcript